Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | October 10, 2017 | October 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date October 10, 2017 · Filed October 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,870 |
Reported balance
After 2017-10-10 transaction · row 1
1 source rowRow 1 · 2017-10-10 · Sale · Disposed 100 · Balance 1,870 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.19 · Expires 2026-10-26 | Direct | 3,985 |
Reported balance
Holding disclosure · report date 2017-10-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,985 F2: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.78 · Expires 2024-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2017-10-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.39 · Expires 2023-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2017-10-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.34 · Expires 2025-10-28 | Direct | 4,260 |
Reported balance
Holding disclosure · report date 2017-10-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,260 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016.
F2: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date March 05, 2019 · Filed March 08, 2019
Section 16 reporting ended · disclosed 2019-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,267 |
Reported balance
After 2019-03-05 transaction · row 1
1 source rowRow 1 · 2019-03-05 · Exercise / conversion · Acquired 8,421 · Balance 102,267 F1: Shares were acquired upon vesting of restricted stock units awarded on May 21, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-05 · Exercise / conversion · Disposed 8,421 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3: 100% of the restricted stock units vested on March 5, 2019, the accelerated vesting date. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired upon vesting of restricted stock units awarded on May 21, 2018.
F2: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock.
F3: 100% of the restricted stock units vested on March 5, 2019, the accelerated vesting date. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2019 Filed Mar 8, 2019 19:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 8,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018291 · doc4.xml · derivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vested on March 5, 2019, the accelerated vesting date. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: 100% of the restricted stock units vested on March 5, 2019, the accelerated vesting date. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 19:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 8,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-018291 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 21, 2018. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:48 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (Right to buy) · Derivative | 13,352 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0001209191-18-032799 · doc4.xml · derivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,352 Underlying: Common Stock · 13,352 shares Expires 2028-05-21 F3 · derivative.exercise_date: The option was granted on May 21, 2018. The award vests and becomes exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:48 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 8,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-032799 · doc4.xml · derivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,421 Underlying: Common Stock · 8,421 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on May 21, 2018 vests on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F2 · derivative.expiration_date: The restricted stock units awarded on May 21, 2018 vests on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $121.96 | $12,195.50 |
DisclosureSEC source: 0001562180-17-003253 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 21:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $120.94 | $12,093.83 |
DisclosureSEC source: 0001562180-17-002935 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 20:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $114.30 | $11,430.00 |
DisclosureSEC source: 0001562180-17-002667 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,070 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 18:11 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 2,250 | $10.07 | $22,666.95 |
DisclosureSEC source: 0001209191-17-047492 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,846 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $9.95 to $10.17 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $116.86 | $11,686.00 |
DisclosureSEC source: 0001562180-17-002467 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $113.62 | $11,362.00 |
DisclosureSEC source: 0001562180-17-002258 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| May 26, 2017 Filed May 30, 2017 19:18 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 20,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-036280 · doc4.xml · derivative · entry 3 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 26, 2017 Filed May 30, 2017 19:18 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 20,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036280 · doc4.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 26, 2016. Read SEC document |
| May 25, 2017 Filed May 30, 2017 19:18 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 12,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036280 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,734 F1 · shares: The restricted stock was awarded on May 25, 2017, and 100% of the restricted stock will vest on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 22, 2017 Filed Jun 1, 2017 20:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,059 | $110.01 | $116,504.83 |
DisclosureSEC source: 0001562180-17-002110 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2017 Filed May 12, 2017 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $110.59 | $11,059.00 |
DisclosureSEC source: 0001562180-17-001934 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:06 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 4,000 | $7.31 | $29,228.40 |
DisclosureSEC source: 0001209191-17-029817 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.11 to $7.40 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 78 | $101.13 | $7,888.14 |
DisclosureSEC source: 0001562180-17-001502 · primarydocument.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 22 | $101.23 | $2,227.06 |
DisclosureSEC source: 0001562180-17-001502 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,529 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 20:43 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 21 | $107.81 | $2,264.01 |
DisclosureSEC source: 0001562180-17-001257 · primarydocument.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,629 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 20:43 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 79 | $107.76 | $8,513.04 |
DisclosureSEC source: 0001562180-17-001257 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $102.60 | $10,260.00 |
DisclosureSEC source: 0001562180-17-000678 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,729 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:42 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 4,000 | $7.32 | $29,290.40 |
DisclosureSEC source: 0001209191-17-007763 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.26 to $7.41 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 22:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $103.57 | $10,357.00 |
DisclosureSEC source: 0001562180-17-000230 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $108.92 | $10,892.48 |
DisclosureSEC source: 0000914190-16-000956 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,929 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $105.75 | $10,575.00 |
DisclosureSEC source: 0000914190-16-000872 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 17:47 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 4,000 | $6.10 | $24,410.80 |
DisclosureSEC source: 0001209191-16-148239 · doc4.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $5.84 to $6.18 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 21:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · derivative · entry 3 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F2 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 21:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,129 Read SEC document |
| October 19, 2016 Filed Oct 31, 2016 21:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $104.71 | $10,471.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,215 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $108.91 | $10,891.00 |
DisclosureSEC source: 0000914190-16-000839 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.